澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

TELIX PHARMACEUTICALS LTD

16.300

+0.4502.84%

成交量：121.39万

成交额：1,974.73万

市值：55.21亿

市盈率：118.87

高：16.500

开：15.950

低：15.840

收：15.850

52周最高：18.220

52周最低：8.260

股本：3.39亿

流通股本：2.75亿

量比：0.86

换手率：0.44%

股息：- -

股息率：- -

每股收益(TTM):0.137

每股收益(LYR):-0.030

净资产收益率：7.36%

总资产收益率：2.71%

市净率：7.88

市盈率(LYR):-537.35

数据加载中...

总览公司新闻资讯公告

Profound Medical与Telix Pharmaceuticals达成共同教育协议，推动基于PSMA的前列腺诊疗发展

Telix Pharmaceuticals旗下Illuccix与Gozellix获批用于PSMA阳性前列腺癌病灶PET成像

Telix Pharma股价在ITM交易引发抛售后反弹；花旗支持其增发股份

每日特惠-并购

Telix Pharmaceuticals——未来监管审批等里程碑达成后，或需支付最高7亿美元额外对价

Telix Pharmaceuticals合并后机构预计2026年未经审计备考营收及收益将突破13亿美元

Telix制药完成调整后，ITM股东预计将获得12.5亿美元Telix股份，每股定价11.841美元

Telix Pharmaceuticals预计2026财年营收及其他收入将突破10亿美元

Telix Pharmaceuticals与摩根士丹利及威廉·布莱尔签署股票分销协议

Telix Pharmaceuticals持续推进：美国生物制品许可申请重新递交进入关键阶段

澳大利亚Telix制药公司因季度营收表现强劲而股价上涨

Telix Pharmaceuticals Ltd 预计2026财年营收及其他收入将突破10亿美元

杰富瑞认为，在ProstACT获FDA批准后，澳大利亚Telix公司有望如期进军美国市场

Telix宣布合作探索PSMA-PET成像在前列腺癌新兴疗法中的应用

TELIX PHARMACEUTICALS LTD可转换债券初始转换价格定为每股13.85美元

Telix制药有限公司初始转换价将高于当前股价

TELIX PHARMACEUTICALS LTD子公司拟发行5.5亿美元2031年到期可转换票据

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/TLX.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":16.3,"timestamp":1791781920000,"preClose":15.85,"halted":0,"volume":1213896,"delay":0,"changeRate":0.02839116719242909,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.13712805384719334,"marketStatus":"未开盘","change":0.45,"latestTime":"10-12 16:12:00 AEDT","open":15.95,"high":16.5,"low":15.84,"amount":19747269,"amplitude":0.04164,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.13712805384719334,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1791846000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":15.85,"openAndCloseTimeList":[[1791759600000,1791781200000]],"volumeRatio":0.858302118791885,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":16.3,"auctionPrice":16.29,"auctionVolume":1042,"auctionTime":1791835375852,"referenceTime":1791801003075,"auction":1,"marketStatus":"盘前竞价","timestamp":1791835375852}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.030334,"volumeRatio":0.858302118791885,"shares":338721355,"dividePrice":0,"high":16.5,"amplitude":0.04164,"preClose":15.85,"low":15.84,"week52Low":8.26,"pbRate":"7.88","psRate":"4.31","week52High":18.22,"institutionHeld":0,"latestPrice":16.3,"eps":0.13712805384719334,"divideRate":0,"volume":1213896,"delay":0,"ttmEps":0.13712805384719334,"open":15.95,"prevYearClose":11.2,"prevWeekClose":15.85,"prevMonthClose":15.72,"prevQuarterClose":15.72,"fiveDayClose":15.55,"twentyDayClose":16.34,"sixtyDayClose":15.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1189105556","title":"Profound Medical与Telix Pharmaceuticals达成共同教育协议，推动基于PSMA的前列腺诊疗发展","url":"https://stock-news.laohu8.com/highlight/detail?id=1189105556","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189105556?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 19:45","pubTimestamp":1791546340,"startTime":"0","endTime":"0","summary":"Profound Medical与Telix Pharmaceuticals签署共同教育协议，旨在推进以PSMA为导向的前列腺护理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143871061","title":"Telix Pharmaceuticals旗下Illuccix与Gozellix获批用于PSMA阳性前列腺癌病灶PET成像","url":"https://stock-news.laohu8.com/highlight/detail?id=1143871061","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143871061?lang=zh_cn&edition=fundamental","pubTime":"2026-09-30 06:23","pubTimestamp":1790720587,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals旗下Illuccix与Gozellix获批用于PSMA阳性前列腺癌病灶PET成像","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669619432","title":"Telix Pharma股价在ITM交易引发抛售后反弹；花旗支持其增发股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2669619432","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669619432?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 09:00","pubTimestamp":1790038804,"startTime":"0","endTime":"0","summary":"BUZZ-Telix Pharma股价在ITM交易引发抛售后反弹；花旗支持其增发股份9月22日-** Telix Pharmaceuticals（TLX.AX）股价一度上涨6.8%至16.83澳元，创下自9月15日以来的最大盘中涨幅** 该公司周一股价下跌11.7%，此前 (link)同意以约16.5亿美元（按无现金、无债务基础计算）收购总部位于德国的ITM Isotope Technologie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4S45E01I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","BK4566","LU0098860793.USD","LU0130102774.USD","LU1668664300.SGD","LU2462157665.USD","LU2456880835.USD","IYF","LU0648001328.SGD","LU1244550221.USD","LU1506573853.SGD","BK4585","LU0170899867.USD","BK7067","LU2125154935.USD","LU2360032135.SGD","LU1244550494.USD","LU0310800965.SGD","LU1244550577.SGD","LU0162691827.USD","LU1144417596.USD","LU2125154778.USD","LU2236285917.USD","TFNS","LU0130517989.USD","FTXO","LU0320765646.SGD","LU1074936037.SGD","LU0203347892.USD","BK4559","BK4504","IE00BSNM7G36.USD","LU0128525689.USD","LU0203345920.USD","LU1201861249.SGD","LU0477156953.USD","LU1366192091.USD","BK4534","BK4588","LU0106831901.USD","LU2417539215.USD","LU0980610538.SGD","TLX.AU","LU0052756011.USD","LU1267930227.SGD","LU1791807156.HKD","LU0072461881.USD","LU0314106906.USD","LU1162221912.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159168","title":"每日特惠-并购","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159168","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669159168?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 19:37","pubTimestamp":1789990660,"startTime":"0","endTime":"0","summary":"每日特惠-并购路透9月21日-截至周一格林尼治标准时间09:30，已报道以下收购要约、合并、收购和资产处置：** 美国烈酒制造商萨泽拉克对饮料公司贝伦岑发起了每股5.55欧元的全面收购要约，该要约已获得贝伦岑监事会和执行董事会的支持。nL8N45D07V** 澳大利亚泰利克斯制药公司TLX.AX表示，已同意以无现金、无债务为基础，以约16.5亿美元收购总部位于德国的ITM Isotope Technologies Munich SE，此举将进一步推动其在放射性药物领域的扩张计划。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL4S45D0R6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK0182","BK1190","BK0084","BK0070","600392","BK1513","BK0233","BK7067","00769","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196839161","title":"Telix Pharmaceuticals——未来监管审批等里程碑达成后，或需支付最高7亿美元额外对价","url":"https://stock-news.laohu8.com/highlight/detail?id=1196839161","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196839161?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 06:43","pubTimestamp":1789944204,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals宣布，若未来实现监管批准等特定里程碑，公司可能面临高达7亿美元（US$700 million）的额外或有对价支付义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121993570","title":"Telix Pharmaceuticals合并后机构预计2026年未经审计备考营收及收益将突破13亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121993570","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121993570?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 06:40","pubTimestamp":1789944009,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals——合并后的组织预计将在2026年产生未经审计的备考收入与收益，其规模有望超越13亿美元大关。这一预期数字，无疑为市场注入了一剂强心针。分析人士指出，如此亮眼的预期业绩，或将进一步巩固Telix Pharmaceuticals在精准医疗及肿瘤诊疗领域的市场地位，并可能对其股价形成正面催化。市场参与者正密切关注该公司后续发布的官方财务指引，以验证这一乐观预期的最终成色。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153719562","title":"Telix制药完成调整后，ITM股东预计将获得12.5亿美元Telix股份，每股定价11.841美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153719562","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153719562?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 06:39","pubTimestamp":1789943949,"startTime":"0","endTime":"0","summary":"Telix制药公司日前披露了与ITM交易相关的进一步细节。经过各项必要调整后，ITM的股东预期将收到总价值高达12.5亿美元的Telix股份作为对价。与此同时，这一股份对价基于每股11.841美元的价格进行计算。这一安排标志着两家公司在整合过程中迈出了关键的一步，亦为ITM股东提供了在Telix整体平台中持续受益的机会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117100091","title":"Telix Pharmaceuticals预计2026财年营收及其他收入将突破10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117100091","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117100091?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 09:55","pubTimestamp":1787190931,"startTime":"0","endTime":"0","summary":"8月20日（路透社）——Telix Pharmaceuticals Limited宣布，其2026财年的营收及其他收入预计将超过10亿美元。该公司上半年集团营收达到4.77亿美元，税后利润为3800万美元。\n此外，Telix已与摩根士丹利和William Blair & Co签署了股权分销协议，旨在建立“按市价”融资机制。这一举措预计将为公司提供更多资本运作的灵活性。\n更多公司详情，请参考TLX.AX的相关报道。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136595917","title":"Telix Pharmaceuticals与摩根士丹利及威廉·布莱尔签署股票分销协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1136595917","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136595917?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 06:47","pubTimestamp":1787179647,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals已与摩根士丹利及威廉·布莱尔公司正式签署了一项股票分销协议。此举标志着该公司在资本市场上的又一重要战略布局，旨在进一步优化其融资渠道并增强财务灵活性。根据该协议，Telix Pharmaceuticals将通过这两家知名金融机构进行股票的分销活动。目前，Telix Pharmaceuticals尚未披露该协议的具体财务条款或预期的发行规模，但市场普遍预计，这一合作将为其带来可观的资本补充，助力其在全球范围内的创新药物研发和商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197836734","title":"Telix Pharmaceuticals持续推进：美国生物制品许可申请重新递交进入关键阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1197836734","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197836734?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 06:45","pubTimestamp":1787179508,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals在重新向美国递交Tlx250-Px（即Zircaix）生物制品许可申请的道路上，正不断取得实质性进展。\n公司表示，朝着近期重新提交这一关键申请的目标，已迈出坚实步伐。这一动向标志着Telix在推动其核心产品进入美国市场的进程中，又向前推进了一步。\n从目前披露的信息来看，Telix Pharmaceuticals显然正以积极的姿态，为Tlx250-Px及Zircaix在美上市铺平道路。市场对此持续关注，而公司的推进节奏也透露出对这款产品前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653226824","title":"澳大利亚Telix制药公司因季度营收表现强劲而股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2653226824","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653226824?lang=zh_cn&edition=fundamental","pubTime":"2026-07-21 13:23","pubTimestamp":1784611422,"startTime":"0","endTime":"0","summary":"BUZZ-澳大利亚Telix制药公司因季度营收表现强劲而股价上涨更新：花旗、杰富瑞研报7月21日-** Telix Pharmaceuticals（TLX.AX）股价一度上涨4.2%至15.73澳元，创下自7月6日以来的最大盘中百分比涨幅** 这家大型生物制药公司 (link) 公布2026年第二季度营收为2.47亿美元，较去年同期增长21%** 预计2026财年营收及其他收入将超过10亿美元**","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nL4T43N0A3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","BK4566","LU0106831901.USD","LU1244550221.USD","BK4585","LU0098860793.USD","LU0320765646.SGD","BK4588","BK4559","LU1791807156.HKD","LU0072461881.USD","LU1244550494.USD","FTXO","LU0170899867.USD","BK4534","LU0130102774.USD","LU1244550577.SGD","LU1074936037.SGD","LU0203347892.USD","BK4504","LU1506573853.SGD","LU2125154935.USD","TLX.AU","BK4207","LU0314106906.USD","LU0162691827.USD","LU0128525689.USD","LU2236285917.USD","LU1162221912.USD","LU0648001328.SGD","LU2360032135.SGD","LU0980610538.SGD","LU2417539215.USD","TFNS","LU2125154778.USD","LU2456880835.USD","LU0310800965.SGD","IYF","LU0203345920.USD","LU1366192091.USD","BK7067","LU1668664300.SGD","LU1267930227.SGD","LU0052756011.USD","LU1201861249.SGD","LU0130517989.USD","LU0477156953.USD","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131203391","title":"Telix Pharmaceuticals Ltd 预计2026财年营收及其他收入将突破10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1131203391","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131203391?lang=zh_cn&edition=fundamental","pubTime":"2026-07-21 06:28","pubTimestamp":1784586493,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd 日前发布预测，公司2026财年的总营收及其他收入有望超过10亿美元大关。这一乐观预期凸显了公司在放射性药物领域强劲的增长势头和市场潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648680520","title":"杰富瑞认为，在ProstACT获FDA批准后，澳大利亚Telix公司有望如期进军美国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2648680520","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648680520?lang=zh_cn&edition=fundamental","pubTime":"2026-07-03 03:26","pubTimestamp":1783020371,"startTime":"0","endTime":"0","summary":"BUZZ-杰富瑞认为，在ProstACT获FDA批准后，澳大利亚Telix公司有望如期进军美国市场7月2日-** 杰富瑞表示，Telix公司针对前列腺癌开展的TLX.AXProstACT临床试验正按计划推进至美国阶段，预计将于2027年公布中期影像学无进展生存期分析数据** 这家医疗科技公司周四表示， (link) 已获美国药品监管机构批准将其全球ProstACT试验的第二部分扩展至美国，并认定第","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nL4T4341I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137496886","title":"Telix宣布合作探索PSMA-PET成像在前列腺癌新兴疗法中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=1137496886","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137496886?lang=zh_cn&edition=fundamental","pubTime":"2026-05-15 18:31","pubTimestamp":1778841068,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd近日宣布，已与多家机构达成合作，旨在探索PSMA-PET成像技术在前列腺癌新兴治疗策略中的潜在应用。这项合作将聚焦于利用先进的分子影像技术，优化前列腺癌的诊断与治疗路径，为患者提供更精准的个性化医疗方案。通过整合影像学与临床治疗数据，研究团队期望能够推动前列腺癌治疗领域的创新突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDAP","BK7067","TLX.AU","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198320680","title":"TELIX PHARMACEUTICALS LTD可转换债券初始转换价格定为每股13.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1198320680","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198320680?lang=zh_cn&edition=fundamental","pubTime":"2026-04-15 06:15","pubTimestamp":1776204911,"startTime":"0","endTime":"0","summary":"TELIX PHARMACEUTICALS LTD（ASX: TLX）近日公布了其即将发行的可转换债券的初始转换价格。根据公告，该转换价格设定为每股13.85美元。这一价格将成为债券持有人未来将其持有的债券转换为公司普通股的基础定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109569829","title":"Telix制药有限公司初始转换价将高于当前股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1109569829","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109569829?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 14:56","pubTimestamp":1776149807,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd（ASX: TLX）最新披露的融资条款显示，其可转换债券的初始转换价格将设定在高于公司当前股价的水平。\n这一溢价定价机制反映了发行方对Telix长期价值增长的信心，同时也为债券持有人提供了潜在的股本增值机会。市场分析人士指出，此类条款常见于成长型生物技术企业的融资结构，既能降低即时股权稀释影响，又能吸引注重长期价值的投资者。\n随着Telix在前列癌诊断放射性药物领域的商业化进程加速，此次融资将为全球市场拓展提供关键资金支持。投资者将密切关注6月30日季度报告中的现金流状况及产品上市进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110649910","title":"TELIX PHARMACEUTICALS LTD子公司拟发行5.5亿美元2031年到期可转换票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1110649910","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110649910?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 14:56","pubTimestamp":1776149791,"startTime":"0","endTime":"0","summary":"TELIX PHARMACEUTICALS LTD（ASX: TLX）宣布，其全资子公司将启动发行规模达5.5亿美元、2031年到期的可转换票据。此次发行为公司战略融资计划的重要组成部分，旨在优化资本结构并支持长期业务发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}